DCM
BLRX

DAFNA Capital Management’s BioLineRX BLRX Stock Holding History

DAFNA Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,634
Closed -$828K – 76
2017
Q2 		$828K Sell
1,634
-33
-2% -$17K 0.59% 47
2017
Q1 		$961K Buy
+1,667
New +$1.07M 0.81% 35

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

DAFNA Capital Management's BLRX Position: Q3 2017 in Review

DAFNA Capital Management sold out of BioLineRX (BLRX) in Q3 2017, closing a stake of 1,634 shares — an estimated $828K sold.

DAFNA Capital Management first reported a position in BLRX in Q1 2017 and held it in 2 quarters. The position peaked at $961K in Q1 2017. 28 funds tracked by Wall St. Rank hold BLRX as of Q3 2017.

  • DAFNA Capital Management reported no remaining BioLineRX position as of Q3 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 1,634 BioLineRX shares in Q3 2017, an estimated $828K.
  • DAFNA Capital Management first reported a position in BioLineRX in Q1 2017 and held it in 2 quarters.
  • DAFNA Capital Management's BioLineRX position peaked at $961K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q3 2017.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.